Scientist/Senior Scientist, Oligonucleotides ADME/PK & Bioanalytics

A*STAR Research; Singapore; On-site; SGD 120,000 - 180,000; Full time

Job summary

NATi, hosted by A*STAR in Singapore, invites applications for Scientist/Senior Scientist to lead ADME/PK and bioanalytics for oligonucleotide therapeutics, accelerating programs from discovery to IND-enabling studies.

PhD in a relevant field and 4–8 years of hands-on oligonucleotide experience are required, with proven PK design, biodistribution expertise, CRO oversight, and strong cross-functional collaboration in a fast-paced startup environment.

Qualifications

• PhD in Pharmacokinetics, Pharmaceutical Sciences, Molecular Biology, or related field.
• A minimum of +4 (Scientist) or +8 (Senior Scientist) years of hands-on experience in preclinical development of oligonucleotide therapeutics
• Demonstrated expertise in PK study design and analysis, Tissue biodistribution, including extrahepatic tissues, and Bioanalytical platforms (qPCR, LC-MS/MS, hybridization assays)
• Hands-on experience leading or contributing to in vivo evaluation of targeted oligonucleotides (e.g., AOCs) with POC for extrahepatic delivery (e.g., Skeletal muscle, adipose tissue)
• Experience integrating biodistribution, PK/PD, and functional outcomes to drive candidate selection
• Experience working in metabolic disease models is highly desirable
• Demonstrated experience in project leadership or scientific ownership within cross-functional teams
• Experience establishing capabilities and working with CRO partners
• Strong analytical rigor and data-driven decision-making
• Effective communicator with the ability to influence cross-functional stakeholders

Responsibilities

• ADME, Pharmacokinetics & Translational Strategy: Design, execute, and interpret PK studies for oligonucleotides in rodent and non-rodent models.
• Bioanalytical Strategy: Develop, validate, and implement robust bioanalytical assays for oligonucleotide quantification in plasma and tissues.
• Cross-functional & Project Leadership: Provide scientific leadership for ADME/PK components and oversee external CRO studies.

Skills

PK study design

Tissue biodistribution

Bioanalytical platforms

Project leadership

Data-driven decisions

Communication

Education

PhD in Pharmacokinetics, Pharmaceutical Sciences, Molecular Biology, or related field

Tools

qPCR

LC-MS/MS

Hybridization assays

Job description

Scientist/Senior Scientist - Oligonucleotides ADME/PK & Bioanalytics By continuing to use and navigate this website, you are agreeing to the use of cookies. Requisition ID: 1655 Posting Start Date: 10/04/2026

Job Description

About NATi

The Nucleic Acid Therapeutics Initiative (NATi), hosted by A*STAR, is Singapore's national platform dedicated to advancing RNA-based medicines and revolutionising drug and vaccine development. NATi's mission is to establish Singapore as a globally recognised hub of excellence in nucleic acid therapeutics research, clinical translation, and commercialisation. NATi focuses on key RNA modalities such as antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and messenger RNA (mRNA). To drive this vision, NATi is building a biotech-like translational engine focused on asset and technology development spanning discovery to clinical development. We are actively seeking passionate and committed individuals with deep translational expertise to join us in advancing the next generation of RNA-based therapeutics.

Position Summary

We are seeking a highly motivated Scientist/Senior Scientist to lead and support ADME, pharmacokinetics (PK), biodistribution, and bioanalytical strategy for oligonucleotide therapeutics. This role will be central in advancing programs from discovery through preclinical development by enabling quantitative understanding of exposure, tissue distribution, target engagement, and PK/PD relationships. The successful candidate will lead the design and execution of preclinical DMPK strategies, integrate PK/PD and biodistribution data to inform candidate selection, and drive translational strategy to support IND-enabling studies. This position requires deep expertise in oligonucleotide PK, rigorous analytical thinking, and the ability to operate effectively in a fast-paced, cross-functional startup environment.

Key Responsibilities

1. ADME, Pharmacokinetics & Translational Strategy

• Design, execute, and interpret PK studies for different oligonucleotides in rodent and non-rodent models.
• Characterize absorption, tissue distribution, metabolism, and excretion (ADME) of oligonucleotides with emphasis on both hepatic and extrahepatic tissue exposure (e.g., muscle, adipose tissue) where relevant; Establish in vitro and/or ex vivo assays to assess molecule’s stability, protein binding, and metabolite profiling as needed.
• Link molecule exposure (PK) to pharmacodynamic (PD) effects (e.g., target knockdown, steric blocking, pharmacological response)
• Design and interpret single- and repeat-dose PK studies to support dose selection, regimen optimization, and translational modelling.
• Lead and be accountable for preclinical proof-of-concept (POC) for targeted oligonucleotide platforms (e.g., antibody-oligonucleotide conjugates/AOCs) for extrahepatic delivery (e.g., muscle, adipose tissue)

2. Bioanalytical Strategy

• Develop, validate, and implement robust bioanalytical assays for oligonucleotide quantification in plasma and tissues (e.g., qPCR-based assays, SL-RT-PCR, Hybridization ELISA, LC-MS/MS)
• Ensure assays are fit-for-purpose with appropriate sensitivity, specificity, and dynamic range, particularly for low-abundance tissues
• Support biomarker strategies (e.g., target mRNA knockdown, protein modulation).
• Ensure regulatory alignment (GLP where applicable).

3. Cross-functional & Project Leadership

• Provide scientific and project leadership for ADME/PK components of oligonucleotide programs, particularly those focused on extrahepatic delivery
• Partner closely with discovery biology/, oligonucleotide chemistry, and bioconjugation scientists.
• Contribute to IND-enabling studies and regulatory documentation.
• Oversee external CRO studies, ensuring scientific quality, timelines, and strategic alignment

Qualifications & Professional Attributes

• PhD in Pharmacokinetics, Pharmaceutical Sciences, Molecular Biology, or related field.
• A minimum of +4 (Scientist) or +8 (Senior Scientist) years of hands‑on experience in preclinical development of oligonucleotide therapeutics
• Demonstrated expertise in PK study design and analysis, Tissue biodistribution, including extrahepatic tissues, and Bioanalytical platforms (qPCR, LC-MS/MS, hybridization assays)
• Hands‑on experience leading or contributing to in vivo evaluation of targeted oligonucleotides (e.g., AOCs) with demonstrated success in POC for extrahepatic delivery (e.g., Skeletal muscle, adipose tissue)
• Experience integrating biodistribution, PK/PD, and functional outcomes to drive candidate selection
• Experience working in metabolic disease models is highly desirable
• Demonstrated experience in project leadership or scientific ownership within cross-functional teams
• Experience establishing capabilities and working with CRO partners
• Strong analytical rigor and data-driven decision-making
• Effective communicator with the ability to influence cross-functional stakeholders

Global Recruitment & Competitive Compensation

NATi is conducting a global search for top-tier talent in RNA therapeutics. We welcome applications from leading pharmaceuticals scientists and biotech innovators worldwide. This role provides a highly competitive compensation package aligned with global industry standards, including attractive benefits and long-term career growth opportunities within Singapore's thriving biomedical innovation ecosystem. Join us in shaping the future of RNA-based medicines and establishing Singapore as a world-class hub for nucleic acid therapeutics.

The above eligibility criteria are not exhaustive. A*STAR may include additional selection criteria based on its prevailing recruitment policies. These policies may be amended from time to time without notice. We regret that only shortlisted candidates will be notified.